Preliminary report: Hydroxyurea produces significant clinical response in thalassemia intermedia

Annals of the New York Academy of Sciences

Volumn 850, Issue , 1998, Pages 461-462

  Styles, Lori ^a   Lewis, Bradley ^b   Foote, Dru ^a   Cuda, Lezlee ^b   Vichinsky, Elliott P ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b Alta Bates Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; HYDROXYUREA;

ADULT; BLOOD TRANSFUSION; CASE REPORT; CHELATION THERAPY; CONFERENCE PAPER; DRUG EFFICACY; FEMALE; HUMAN; IRON OVERLOAD; LIFE EXPECTANCY; MALE; MORBIDITY; NORTH AMERICA; PRESCHOOL CHILD; THALASSEMIA;

EID: 0031824744     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1998.tb10521.x     Document Type: Conference Paper

References (4)

1. MONZON, C. M. et al. 1986. Hereditary red cell disorders in Southeast Asian refugees and the effect on the prevalence of thalassemia disorders in the United States. Am. J. Med. Sci. 292: 147-151.
2. HAJJAR, F. M. & H. A. PEARSON. 1994. Pharmacologic treatment of thalassemia intermedia with hydroxyurea. J. Pediatr. 125: 490-492.
3. FUCHAROEN, S. et al. 1996. Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in β-thalassemia/Hemoglobin E disease. Blood 87: 887-892.
4. ZENG, Y-T. et al. 1995. Hydroxyurea therapy in β-thalassemia intermedia: improvement in haematological parameters due to enhanced β-globin synthesis. Br. J. Haematol. 90: 557-563.